[The clinical characteristics and immunotherapy of complicated forms of adenovirus keratoconjunctivitis].
Analysis of case histories and clinical and direct immunofluorescent examinations of 72 patients enabled the authors to single out 3 forms of complicated adenovirus keratoconjunctivitis (AVKC): 1) acute grave; 2) with toxic allergic reaction to previous treatment; and 3) steroid-complicated. Recommendations on the treatment of these forms are offered. A common remedy is interferon inductor poludan and chigain obtained from human colostrum and containing secretory IgA. Poludan was administered by instillations (4-6 times a day) and periocular injections in a dose of 100 U every 1-2 days, 5-6 injections per course, chigain was administered by instillations (2-4 daily). This combined treatment was highly effective and well tolerated. Periocular injection of poludan ensured much more intensive local and even systemic interferon production than instillations alone. Mean terms of treating complicated AVKC were compatible with those in uncomplicated forms: 14.3 +/- 2.1 vs. 13.2 +/- 1.2 days, respectively. Signs of herpesvirus infection were detected in one-third of patients with steroid-complicated AVKC. For eliminating corneal opacities in AVKC patients, enzyme phonophoresis, phototherapeutic keratectomy, and (in grave cases) lamellar keratoplasty are recommended.
Krasnov
M M
MM
Kasparov
A A
AA
Kasparova
E A
EA
D000208:Acute Disease; D000258:Adenovirus Infections, Human / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use; D001685:Biological Factors / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D007369:Interferon Inducers / Q000009:adverse effects / Q000627:therapeutic use; D007637:Keratoconjunctivitis / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D008297:Male; D011131:Polyribonucleotides / Q000009:adverse effects / Q000627:therapeutic use
D000998:Antiviral Agents; D001685:Biological Factors; D004338:Drug Combinations; D007071:Immunoglobulin A, Secretory; D007369:Interferon Inducers; D011131:Polyribonucleotides; C085744:chigain; C044366:poludan
Klinicheskie osobenoosti i immunoterapiia oslozhnennykh form adenovirusnogo keratokon''iunktivita.